Atossa Therapeutics, Inc. (ATOS)

Over the past six months, Atossa completed a Type C meeting with the FDA and received Rare Pediatric Disease Designation and Orphan Drug Designation for (Z)-Endoxifen. The company issued a letter to shareholders highlighting accomplishments and the 2026 outlook, with the stock price reaching a 52-week low. Atossa reported its Fourth Quarter and Year-End 2025 financial results, announcing it would not proceed with advancing (Z)-Endoxifen in metastatic breast cancer. Pre-clinical data for (Z)-Endoxifen in DMD was presented at a conference. Phase 2 trial results for (Z)-Endoxifen were published, and the company received FDA Rare Pediatric Disease Designation for McCune-Albright Syndrome. Atossa reported its First Quarter 2026 financial results, with the stock price declining and a reverse stock split mentioned.

Atossa Therapeutics, Inc. does not have approved products on the market, so there is no direct product or service demand seasonality. The company's business model is focused on research and development, clinical trial execution, and regulatory strategy, which are not subject to seasonal demand fluctuations.

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative medicines in oncology, particularly breast cancer and related conditions, and rare diseases. Their lead product candidate is (Z)-Endoxifen, an oral formulation being evaluated in Phase 2 clinical development for breast cancer treatment and prevention, as well as rare diseases like Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS). The company has a growing global intellectual property portfolio around (Z)-Endoxifen.

Atossa Therapeutics, Inc. is headquartered in Seattle, Washington, United States. Its intellectual property strategy has a global reach, with patents and applications worldwide for (Z)-Endoxifen.

Atossa Therapeutics' brand reputation has been shaped by clinical advancements and regulatory interactions. Positive events include Phase 2 trial results for (Z)-Endoxifen and FDA designations for DMD and McCune-Albright Syndrome. Ongoing litigation with Intas Pharmaceuticals and the decision to not proceed with (Z)-Endoxifen in metastatic breast cancer could affect reputation. The company's financial results also contribute to its public perception.

Atossa Therapeutics, Inc. is owned by a combination of institutional and individual shareholders. Institutional shareholders collectively own 255.24% of the stock. Shuchih Chen is the largest individual shareholder, owning 105.62% of the company. Insiders own 166.92% of the company.